(+) Halozyme Therapeutics and Zalicus recent movers in a booming industry (Marketwire) - Aug 9, 2012 - Zalicus stocks were up by 12% on Tuesday Aug 7, 2012
Stock price • Pain
|
|
Zalicus is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. The company reported that for the second quarter 2012 revenue was $2.9 million compared to $1.8 million for the second quarter 2011. Shares of the company surged nearly 12 percent Tuesday.
(IR4)
|